These findings fit with recent reports of elevated glutamatergic neurotransmission and plasticity of the ACC in patients with BD, say the researchers, led by Hans-Gert Bernstein, from the University of Magdeburg in Germany. It appears conceivable that more extensive dysregulation of the conversation between glutamatergic and monoaminergic neurotransmission might occur in BD, and that altered expression of AKAP5 as an integrator of glutamatergic and monoaminergic signalling cascades may be a signature of such a dysregulation, they describe.Silberstein, MD, FACP, both of the Jefferson Headaches Center of Thomas Jefferson University, and by Todd J. Schwedt, MD, MSCI, of the Department of Neurology, Mayo Clinic Arizona. The authors, who are users of the Guidelines Section of AHS, up to date the acute migraine treatment guidelines released in 2000 by the American Academy of Neurology and the AHS. They used AAN Suggestions Development Procedures to conduct a thorough overview of latest scientific literature on this topic. The AHS and AAN recently published joint guidelines on the prevention of migraine attacks also. ‘We hope that evaluation of the efficacy of currently available migraine therapies assists patients and their physicians utilize treatments that will be the most appropriate for them,’ said Dr. Silberstein.